or Connect
HotStockMarket › Forums › HSM Stock Forum › Penny Stocks › CBIS - Cannabis Science
New Posts  All Forums:Forum Nav:

CBIS - Cannabis Science - Page 5  

post #81 of 1303
Thread Starter 

Play Em

Quote:
Originally Posted by bmwe30mstyle View Post
I can fly high up to the sky... wow I really need to play these herbals

Is that a microphone seeker?
LOL , kinda lookes like it. I really like those charts.
post #82 of 1303
Thread Starter 
With CBIS I still believe that .72 is a very likely possibility for Today perhaps higher. I have noticed increased commentary widespread among other message mediums. However CBIS should at some point see a retrace that will offer a nice entry point for its journey to the 1.05 that the chart suggests.
Just keep your eyes on its development as this stock seems to climb steadily throughout the course of the day.
JMO
post #83 of 1303
This is on the run
post #84 of 1303
wow,


way to go THseeker, you have called this one from the start. Thanks
post #85 of 1303
Got out at .80, will be looking for that re-entry. Does anyone else actually believe that the FDA will approve cannabis products? I had to ask my broker if I stood any risk of arrest for buying this stock.
post #86 of 1303
nice whoever got in this is lucky! lets see what it will end at today
post #87 of 1303
got out at .83
post #88 of 1303
This is a Beast!! Wish I had gotten in last week.
post #89 of 1303
The movement looks very similar to SPNG recently. watch for a significant retrace soon. Congrats to all who have made money on this, just giving a heads up as to what I feel is to come.
post #90 of 1303
Thread Starter 
CBIS News 1.18 soon IMO

Cannabis Science to Apply to the FDA to Utilize Their Fast Track Procedures to Help Speed the Approval of Its Cannabinoid Medicines in Treatment of H1N1 Swine Flu as AP Report Predicts Swine Flu Could Hit up to 40 Percent in the USA

* Press Release
* Source: Cannabis Science, Inc.
* On Monday July 27, 2009, 1:23 pm EDT

*
Buzz up! 0
* Print

*
Companies:
o Cannabis science, inc.

SAN FRANCISCO, CA--(Marketwire - 07/27/09) - Cannabis Science, Inc. (OTC.BB:CBIS - News), an emerging pharmaceutical cannabis company, is pleased to report that it is moving as fast as possible to assist in the fight against the threat of a deadly influenza pandemic. In conjunction with its recent re-organization, the Company has begun discussions with the FDA as its program moves forward to provide FDA approved solutions for several critical illnesses.
Related Quotes
SymbolPriceChange
CBIS.OB0.8300+0.3505
Chart for CANNABIS SCIENCE INC
{"s" : "cbis.ob","k" : "c10,l10,p20,t10","o" : "","j" : ""}

H1N1 Swine Flu:

According to the CDC (http://www.cdc.gov/flu/avian/) the Avian flu (H5N1) has a 63% mortality rate. Unfortunately, the Swine flu, while causing death at a much lower rate than the Avian flu, appears to also result in death via a similar mechanism. The common cause of death with these strains is organ failure, especially as seen in the lungs with the development of Adult Respiratory Distress Syndrome (ARDS). ARDS is caused by an excess immune-generated inflammatory response that leads to apoptosis (cell death) and subsequently to organ failure. The Company's approach will mimic how the human body uses endocannabinoids (cannabinoids that occur naturally in the body) to regulate immune activity and cell survival, by regulating inflammatory biochemistry. Excessive inflammatory responses are associated with numerous disease states including autoimmune diseases, neurological imbalances, and cardiovascular disease. Phytocannabinoids provide a natural means to supplement illness-specific endocannabinoid deficiencies.

Cannabis Science H1N1 Swine Flu Formulation:

We now know that the endocannabinoid system plays a critical role in maintaining human health. The human body produces Endocannabinoids on demand when they are needed. They help restore homeostasis (biochemical balance). The Cannabis plant produces Phytocannabinoids. When the human body has endocannabinoid deficiencies, it cannot effectively restore the healthy biochemical state needed to counter a particular illness. Phytocannabinoids from the Cannabis plant can replace the deficient endocannabinoid activity in the human body to restore a health-promoting level of cannabinoid activity. Cannabis Science will test its cannabis extract lozenge with FDA guidance and oversight to determine if it will reduce ARDS-associated deaths from both the Avian and Swine influenza infections.

Dr. Robert Melamede, Ph.D., Cannabis Science, Inc., President and CEO, believes there is enormous potential value for cannabinoids to naturally reduce excessive inflammatory immune responses, and the Cannabis Science lozenge formulation could reduce the mortality rate and allow infected individuals to develop a strong natural immunity upon recovery. Dr. Melamede is the former Chairman (ret) of the Biology Department at the University of Colorado (Colorado Springs.)

Dr. Melamede added, "Again, we recommend, based on sound scientific principles, that medical marijuana users should switch to edibles if they come down with an influenza infection. We believe that the irritation associated with the pulmonary route, when a person has an influenza infection, may lead to unnecessary deaths. In contrast, oral administration may prevent many deaths. We hope that due to the magnitude of this pandemic threat, that the FDA will fast track our proposal."

FDA's three rapid special drug release programs:

Fast Track, Accelerated Approval and Priority Review are approaches that are intended to make therapeutically important drugs available at an earlier time. They do not compromise the standards for the safety and effectiveness of the drugs that become available through this process. These revitalized FDA drug review approaches have yielded tangible results in bringing safe and effective drugs to patients with serious diseases more quickly. For example, since 1996, 68 drugs for cancer therapies have received priority review and approval. The FDA reviewed Gleevec, a treatment for chronic myeloid leukemia, in four months. Shortened review times have also brought promising treatments to patients with HIV/AIDS more quickly. Kaletra for the treatment of HIV/AIDS was reviewed and approved in 3.5 months. Pegasys, a combination product for the treatment of Hepatitis C, was approved for marketing in 4 months.

Fast Track, Accelerated Approval, and Priority Review have evolved over time. The FDA has been vigilant in assuring that reducing the time necessary for drug development has not compromised the safety and effectiveness of drugs for patients with serious diseases. The median time required to review a priority review drug was reduced from 13.9 months to 6.7 months.

About Cannabis Science, Inc.

Cannabis Science, Inc. is at the forefront of medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
post #91 of 1303
great job seeker, very very nice.
post #92 of 1303
mann this stock is on steroid
post #93 of 1303
which id do less smokin and more buyin. . what .15 just a week ago? unfknreal
post #94 of 1303
well, I am a greedy bastard. I am out, like money to much.


one hell of a ride, and sure wish I would had more from the start.
post #95 of 1303
holy F this thing took off... i originally saw this thread when the price was .07. hating myself for not doin some DD
post #96 of 1303
I can't believe you guys are having this discussion, but study after study has shown that marijuana is harmless. Alchohol and tobacco are much more harmful to the user.

If you're really interested, go research the history of why marijuana became illegal in the first place. Today, we are spending billions of dollars on this 'war on drugs' that originally started as a political campaign for alcohol, tobacco, and lumber lobbyists.

With the current state of the economy, states like California are eventually going to have to acknowledge the fact that marijuana has more potential benefits than costs. It's only a matter of time before it's decriminalized, then fully legalized.
post #97 of 1303
man went to the gym and came back, unreal!! so what"s everyones prediction for the rest of the week?
post #98 of 1303
Think it will follow suit with other FDA stocks for the time being. $1.50 52week high. sounds like target price IMO
post #99 of 1303
pumped out the a$$, and going to be dumped the same way, it will be a slick ride out. Look at the 6 month chart
You could probably play the dips on the way down, but the PR released today reminds me of the one back when NVAX ran like 500% and it went something like: OMG SWINE FLU COMING TO A NEIGHBOR NEAR YOU!!
I shorted NVAX and took home 120% profit on that one...too bad I couldnt do the same thing here
post #100 of 1303
I'm going to say Friday's price will be around .83 with an EOD selloff to bring us back to .75-.78 ALL IMO
New Posts  All Forums:Forum Nav:
  Return Home
  Back to Forum: Penny Stocks
This thread is locked  
HotStockMarket › Forums › HSM Stock Forum › Penny Stocks › CBIS - Cannabis Science